Trial · NCT07079761
Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.
NCT07079761, Phase 2, Recruiting, Massachusetts General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD. Trials, record NCT07079761. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07079761
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.
- NCT number
- NCT07079761
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 96 participants, estimated
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Post Traumatic Stress Disorder
- Interventions
Experiment 1: Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Matching IV Placebo, Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm, Matching IV Placebo
- First posted
- 2025-07-23
- Last updated
- 2025-11-05
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Experiment 1: Extinction retention | Day 3 | Extinction retention is calculated as a) the difference between the average skin conductance response (SCR) to the first 4 aversively conditioned stimulus (CS+) trials and the average SCR to first 4 neutral conditioned stimulus (CS-) trials on Day 3 minus b) the difference between the average SCR to the last 4 CS+ trials and last 4 CS- trials on Day 2. |
| Primary | Experiment 2: Reconsolidation blockade | Day 3 | Reconsolidation blockade will be assessed by calculating the average fear potentiated startle (FPS) response to the first 4 CS+ trials on Day 3. Lower scores indicate better reconsolidation blockade. |
| Secondary | Experiment 1: Reinstatement of conditioned fear | Day 3 | Reinstatement of conditioned fear will be assessed by calculating the average SCR to the last 4 CS+ trials minus the average SCR to the last 4 CS- trials on Day 3. |
| Secondary | Experiment 2: Reinstatement of conditioned fear | Day 3 | Reinstatement of conditioned fear will be assessed as the average FPS to the last 4 CS+ trials on Day 3. Higher scores indicate greater reinstatement of conditioned fear. |
| Secondary | Reinstatement of Conditioned Fear in Expt. 1 | Day 3 | Reinstatement of conditioned fear will be defined as the average SCR to the last 4 CS+ trials minus the average SCR to the last 4 CS- trials. For FPS, the last 4 CS+ trials will be examined. Higher scores indicate greater reinstatement of conditioned fear. |
| Secondary | Reinstatement of Conditioned Fear in Expt. 2 | Day 3 | Reinstatement of conditioned fear will be defined as the average SCR to the last 4 CS+ trials minus the average SCR to the last 4 CS- trials. For FPS, the last 4 CS+ trials will be examined. Higher scores indicate greater reinstatement of conditioned fear. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01MH122867 | Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD | RASMUSSON, ANN M. | BOSTON UNIVERSITY MEDICAL CAMPUS | NATIONAL INSTITUTE OF MENTAL HEALTH | 2020 to 2023 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07079761
GET https://conductscience.org/api/trials/v1/NCT07079761/registered